A Cost Utility Analysis of CYP2D6 Pharmacogenetic Guided Dosing Versus Standard Dosing of Risperidone for Treatment of Schizophrenia

Value in Health - United Kingdom
doi 10.1016/j.jval.2014.03.1271
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Risperidone Versus Placebo for Schizophrenia

Cochrane Database of Systematic Reviews
2016English

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults With Schizophrenia

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2016English

Economic Evaluation of a Pharmacogenetic Dosing Algorithm for Coumarin Anticoagulants in the Netherlands

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2015English

A Cost-Utility Analysis of Amisulpride and Paliperidone in the Treatment of Schizophrenia

Heliyon
Multidisciplinary
2019English

CYP2C9*8is Prevalent Among African–Americans: Implications for Pharmacogenetic Dosing

Pharmacogenomics
Molecular MedicineGeneticsPharmacology
2009English

Single Versus Multiple Daily Dosing of Lithium

Journal of Clinical Psychiatry
MedicinePsychiatryMental Health
2005English

Pharmacogenetics-Guided Dosing for Fluoropyrimidines in Cancer Chemotherapy

Advances in Pharmacoepidemiology & Drug Safety
2014English

Genotype-Guided Versus Traditional Clinical Dosing of Warfarin in Patients of Asian Ancestry: A Randomized Controlled Trial

BMC Medicine
Medicine
2018English

Pmh42 - Cost-Utility Analysis of Cariprazine Compared to Risperidone Among Patients With Negative Symptoms of Schizophrenia in Selected Nordic Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy